Executive’s Guide
To the world’s leading pharmaceutical and biotechnology companies
The Executive's Guide 2008 is an indispensable reference for those seeking a strategic insight into the biopharmaceutical industry and its major players. This year's edition - the 21st to date - provides a snapshot of the world's top 25 pharmaceutical and biotechnology companies, ranked by ethical drug sales, and includes an analysis of the key issues facing each company, their strategies, portfolios and pipelines. Each company executive summary also includes a breakdown of ethical drug sales by geography and therapeutic area, company earnings-per-share and dividend-per-share performance, as well as a five-year portfolio freshness index.
In addition, the Executive's Guide 2008 ranks the top 100 ethical drugs by sales, and identifies the key themes that will affect the industry in the near-term. It also explores the major products and players in 14 different therapy areas, and looks at the underlying factors affecting the dynamics of these therapy areas.
The 2008 edition includes:
- Analysis of the four key issues facing the industry in the near-term
- The top 100 ethical drugs ranked by sales in 2007
- Analysis of the 14 major therapy areas, including key products, sales and growth rates
- The top 25 pharmaceutical and biotechnology companies ranked by 2007 ethical drug sales
- Executive summaries for each of the top 25 pharmaceutical and biotechnology companies
- Analysis of the dividend growth and share repurchases for the top 10 companies in 2007